3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Urinary Bladder Neoplasms
3
Carcinoma, Transitional Cell
3
Urethral Neoplasms
2
Ureteral Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Recurrence
1
Prostatic Neoplasms
1
Penile Neoplasms
1
Neoplasms
1
Carcinoma, Small Cell
1
Carcinoma
1
Breast Neoplasms, Male
1
Interventions
Gemcitabine
11
Cisplatin
11
Nivolumab
4
Doxorubicin
4
pembrolizumab
3
avelumab
3
Radiotherapy
3
Fluorouracil
3
Docetaxel
3
Carboplatin
3
vinflunine
2
pegfilgrastim
2
Sunitinib
2
Platinum
2
Paclitaxel
2
Immunoglobulin G
2
Ifosfamide
2
Disulfides
2
1,2-diaminocyclohexaneplatinum II citrate
2
vandetanib
1
tremelimumab
1
tocilizumab
1
temsirolimus
1
tamibarotene
1
relatlimab
1
merphos
1
guadecitabine
1
enzalutamide
1
durvalumab
1
dehydroftorafur
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Urethral Neoplasms
×
vinflunine
×
Clear all
NCT02665039
2019-10-08
VINGEM
Karolinska University Hospital
Phase 2
Completed
62 enrolled
NCT01844947
2019-04-26
VINSOR
Karolinska University Hospital
Phase 1
Completed
22 enrolled